endra life sciences inc - NDRA

NDRA

Close Chg Chg %
5.08 -0.26 -5.12%

Closed Market

4.82

-0.26 (5.12%)

Volume: 35.18K

Last Updated:

Dec 29, 2025, 4:00 PM EDT

Company Overview: endra life sciences inc - NDRA

NDRA Key Data

Open

$4.89

Day Range

4.65 - 4.97

52 Week Range

2.90 - 11.96

Market Cap

$5.93M

Shares Outstanding

1.17M

Public Float

903.40K

Beta

-0.33

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$13.39

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

83.42K

 

NDRA Performance

1 Week
 
-5.12%
 
1 Month
 
-18.44%
 
3 Months
 
-16.17%
 
1 Year
 
-23.49%
 
5 Years
 
-99.98%
 

NDRA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About endra life sciences inc - NDRA

ENDRA Life Sciences, Inc. engages in the development of medical devices for accurate liver fat measurement for use in metabolic disease detection and GLP-1 drug eligibility and management. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.

NDRA At a Glance

ENDRA Life Sciences, Inc.
3600 Green Court
Ann Arbor, Michigan 48105-1570
Phone 1-734-335-0468 Revenue 0.00
Industry Medical Specialties Net Income -11,507,947.00
Sector Health Technology Employees 21
Fiscal Year-end 12 / 2025
View SEC Filings

NDRA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 1.313
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.077
Enterprise Value to Sales N/A
Total Debt to Enterprise Value -0.424

NDRA Efficiency

Revenue/Employee N/A
Income Per Employee -547,997.476
Receivables Turnover N/A
Total Asset Turnover N/A

NDRA Liquidity

Current Ratio 5.673
Quick Ratio 5.673
Cash Ratio 5.336

NDRA Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -205.38
Return on Equity -280.021
Return on Total Capital -365.937
Return on Invested Capital -258.638

NDRA Capital Structure

Total Debt to Total Equity 22.826
Total Debt to Total Capital 18.584
Total Debt to Total Assets 13.126
Long-Term Debt to Equity 19.04
Long-Term Debt to Total Capital 15.501
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Endra Life Sciences Inc - NDRA

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
224.41K 234.26K 275.45K 206.17K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
224.41K 234.26K 275.45K 206.17K
Depreciation
224.41K 234.26K 275.45K 206.17K
Amortization of Intangibles
- - - -
-
COGS Growth
+35.80% +4.39% +17.58% -25.15%
Gross Income
(224.41K) (234.26K) (275.45K) (206.17K)
Gross Income Growth
-35.80% -4.39% -17.58% +25.15%
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
11.27M 12.92M 10.25M 10.61M
Research & Development
5.48M 6.55M 5.00M 3.19M
Other SG&A
5.79M 6.37M 5.24M 7.42M
SGA Growth
-0.55% +14.63% -20.72% +3.57%
Other Operating Expense
- - - 7.32M
-
Unusual Expense
- - (308.60K) (3.08M)
-
EBIT after Unusual Expense
(11.19M) (13.16M) (10.52M) (15.06M)
Non Operating Income/Expense
(41.54K) (21.53K) 460.48K 3.56M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(11.23M) (13.18M) (10.06M) (11.51M)
Pretax Income Growth
+4.22% -17.34% +23.67% -14.39%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(11.23M) (13.18M) (10.06M) (11.51M)
Minority Interest Expense
- - - -
-
Net Income
(11.23M) (13.18M) (10.06M) (11.51M)
Net Income Growth
+4.22% -17.34% +23.67% -14.39%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(11.23M) (13.18M) (10.06M) (11.51M)
Preferred Dividends
- - - 121.07K
-
Net Income Available to Common
(11.35M) (13.18M) (10.06M) (11.51M)
EPS (Basic)
-9709.35 -7976.85 -2766.5225 -56.9402
EPS (Basic) Growth
+56.08% +17.84% +65.32% +97.94%
Basic Shares Outstanding
1.17K 1.65K 3.64K 202.11K
EPS (Diluted)
-9709.35 -7976.85 -2766.5225 -56.9402
EPS (Diluted) Growth
+56.08% +17.84% +65.32% +97.94%
Diluted Shares Outstanding
1.17K 1.65K 3.64K 202.11K
EBITDA
(11.27M) (12.92M) (10.25M) (17.93M)
EBITDA Growth
+0.55% -14.63% +20.72% -75.05%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 38.00
Number of Ratings 1 Current Quarters Estimate -1.23
FY Report Date 12 / 2025 Current Year's Estimate -6.59
Last Quarter’s Earnings -2.10 Median PE on CY Estimate N/A
Year Ago Earnings -56.94 Next Fiscal Year Estimate -4.62
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 1
Mean Estimate -1.23 -1.23 -6.59 -4.62
High Estimates -1.23 -1.23 -6.59 -4.62
Low Estimate -1.23 -1.23 -6.59 -4.62
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Endra Life Sciences Inc in the News